{"id":287763,"date":"2026-10-05T16:46:44","date_gmt":"2026-10-05T11:16:44","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=287763"},"modified":"2026-10-05T16:46:44","modified_gmt":"2026-10-05T11:16:44","slug":"lords-mark-industries-share-price-uk-ivd-launch-mhra","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/lords-mark-industries-share-price-uk-ivd-launch-mhra\/","title":{"rendered":"Lords Mark Industries Share Price Rises 4% in a Relief Rally: UK MHRA Registration, IVD Sales From December 2026, a Stock Under Rs 100 and the Risks Owners Should Weigh"},"content":{"rendered":"

Lords Mark closed Rs 81.47 (+2.57%) on 5 Oct after a 4% intraday jump. UK MHRA registration; IVD sales from Dec 2026. Mcap Rs 3,394 cr; 88% below 52-week high.<\/em><\/p>\n

\n

Quick Answer<\/strong><\/p>\n

Lords Mark Industries share price rose over 4% during the session on 5 October and closed 2.57% higher at Rs 81.47 after the company said it had received UK MHRA registration for its in-vitro diagnostics (IVD) portfolio, which clears the way for commercial sales in Great Britain from December 2026, two months earlier than planned. The registration covers haematology and clinical chemistry analysers, sample diluents and cleaning agents, and a separate MHRA registration for its AI-powered dialysis range followed on 28 September. The stock is a small-cap under Rs 100 with a market capitalisation near Rs 3,394 crore, still about 88% below its 52-week high of Rs 669.70, so the rally is a relief bounce and not a recovery. Valuation near 43 times earnings, long receivable days and heavy volatility are the main risks for holders.<\/p>\n<\/p><\/div>\n

Lords Mark Industries share price rose more than 4% on Monday, 5 October, as small caps joined the relief rally on Dalal Street. The stock closed at Rs 81.47, up 2.57% from Rs 79.43, after the company announced progress on UK regulatory approvals for its medical diagnostics business.<\/p>\n

If you own the stock, or are wondering whether to, this article covers the business update, the MHRA registration and the December IVD launch, the AI dialysis range, the Silvassa expansion, the FY27 revenue target, the small-cap’s market capitalisation and valuation, the 52-week high and price history, promoter selling and the risks. Data is from company disclosures and market reports, and figures differ by provider, so recheck before acting.<\/p>\n

Click Here – Get Free Investment Predictions<\/a><\/strong><\/p>\n

\n
\n

Table of Contents<\/p>\nToggle<\/span><\/path><\/svg><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n